Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming
Ontology highlight
ABSTRACT: Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming
PROVIDER: PRJNA588271 | ENA |
REPOSITORIES: ENA
ACCESS DATA